EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Reply to Trudeau, M.; Fraser, B. The CADTH pCODR Expert Review Committee Process Explained. Comment on “Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29, 9891–9895”

Daniel Rayson, Sonal Gandhi, Anil A Joy, Christine Brezden-Masley iD, Karen A Gelmon, Sandeep Sehdev, David Cescon, Stephen Chia

Current Oncology · 2023

DOI: 10.3390/curroncol30050381 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Oncology, 2023. Verfasst von Daniel Rayson und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Medicine, Queen Elizabeth II Health Sciences Center, Halifax, NS B3H 2Y9, Canada. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We appreciate the opportunity to respond to the comment [...]

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsHumansFemaleTrastuzumabNeoadjuvant TherapyAdvisory CommitteesErb-b2 Receptor Tyrosine KinasesCanadaAntibodies, Monoclonal, Humanized

Substanzen

TrastuzumabErb-b2 Receptor Tyrosine KinasespertuzumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Division of Medical Oncology, Department of Medicine, Queen Elizabeth II Health Sciences Center, Halifax, NS B3H 2Y9, Canada.
  • Division of Medical Oncology/Hematology, Odette Cancer Centre Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada.
  • Division of Medical Oncology, Cross Cancer Institute, Edmonton, AB T6G 1Z2, Canada.
  • Division of Medical Oncology, Mount Sinai Hospital, Toronto, ON M5G 1X5, Canada.
  • Division of Medical Oncology, British Columbia Cancer Centre, Vancouver, BC V5Z 4E6, Canada.
  • Department of Medical Oncology, The Ottawa Hospital Cancer Centre, Ottawa, ON K1H 8L6, Canada.

ORCID-Profile: Christine Brezden-Masley

Zitieren

APA

Rayson, D., Gandhi, S., Joy, A. A., Brezden-Masley, C., Gelmon, K. A., Sehdev, S., Cescon, D., & Chia, S. (2023). Reply to Trudeau, M.; Fraser, B. The CADTH pCODR Expert Review Committee Process Explained. Comment on “Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29, 9891–9895”. Current Oncology. https://doi.org/10.3390/curroncol30050381

Vancouver

Rayson D, Gandhi S, Joy AA, Brezden-Masley C, Gelmon KA, Sehdev S, et al. Reply to Trudeau, M.; Fraser, B. The CADTH pCODR Expert Review Committee Process Explained. Comment on “Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29, 9891–9895”. Current Oncology. 2023. doi:10.3390/curroncol30050381

BibTeX
@article{Rayson2023,
  author = {Rayson, Daniel and Gandhi, Sonal and Joy, Anil A and Brezden-Masley, Christine and Gelmon, Karen A and Sehdev, Sandeep and Cescon, David and Chia, Stephen},
  title = {Reply to Trudeau, M.; Fraser, B. The CADTH pCODR Expert Review Committee Process Explained. Comment on “Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29, 9891–9895”},
  journal = {Current Oncology},
  year = {2023},
  doi = {10.3390/curroncol30050381}
}
Kostenlos starten →